Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage

This trial is studying whether a specific protein marker (Cyclin D1) in tumors can help predict which oral cancer patients will respond best to a three-drug chemotherapy combination (called TPF) given before surgery or radiation. **You may be eligible if...** - You are between 18 and 75 years old - You have been confirmed by biopsy to have squamous cell carcinoma (a common type of cancer) in your mouth or oral cavity - Your tumor shows high expression of the Cyclin D1 protein - Your cancer is at clinical stage III or IVA with lymph node involvement (N2) and can be surgically removed - Your blood counts and organ function meet the required levels **You may NOT be eligible if...** - Your cancer is at a different stage or location - Your Cyclin D1 expression is low - Your general health or organ function is too poor for chemotherapy - You are pregnant Talk to your doctor to see if this trial is right for you.